The Effects of Ambrisentan on Exercise Capacity in Fontan Patients

Hypothesis:

Patients with a Fontan type palliation are limited by preload, or the rate at which blood returns to the heart after passively traversing the pulmonary capillary bed. By decreasing pulmonary vascular resistance using an endothelin receptor antagonist, both ventricular filling pressures and volumes will increase with a simultaneous decrease in systemic impedance to flow and decrease in central venous pressures, leading to an improved capacity to increase cardiac output, and thereby an improvement in patient functional status.

Patients who are candidates for the study will be randomized to a double-blind single crossover study. Therapy with either ambrisentan or placebo will be continued for 12 weeks, with a 2 week washout period between treatment periods. Subjects will be subjected to a VO2 max test to evaluate exercise capacity at enrolment, and on the last day of each treatment period. As a component of the VO2 max testing the patient's VE, VCO2, VE/VCO2 slope, ventilatory anaerobic threshold (VAT), peak work, efficiency, and other physiologic parameters as typically obtained from cardiopulmonary testing will be assessed. In addition, each patient will be asked to complete an SF-36 quality of life questionnaire at enrollment, and on the last day of each study period.

Study Overview

• Status: Completed
• Conditions: Single Ventricle Fontan Palliation
• Intervention / Treatment: Drug: Ambrisentan

• Study Type: Interventional
• Enrollment (Actual): 28
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • Missouri
    • Saint Louis, Missouri, United States, 63110
      • Washington University School of Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 48 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Patients over 18 years of age followed at the Center for Adults with Congenital Heart Disease at Washington University School of Medicine or at Saint Louis Childrens Hospital who have had a Fontan-type of palliation with single ventricular physiology.
2. Patients must not within the last year have been treated with an endothelin receptor antagonist, phosphodiesterase 5 antagonist, or prostacyclin analogue.
3. Female patients must not be pregnant, and during the study period must be using effective contraception (including barrier method with spermicide, intrauterine device, implanon, oral contraceptives) if fertile.
4. In the physicians opinion patients must be able to complete a VO2 max test to achieve an RER of >1.0
5. In the physicians opinion patients must be socially and intellectually able to adhere to the treatment regimen and follow-up
6. Patients must be intellectually able to reliably complete an SF-36 questionnaire on quality of life.
7. Patients must be clinically stable for at least 3 months prior to enrolment.
8. Patients must not have had surgery within 6 months prior to enrolment, and have no planned surgery for the study period.

9. Patients must provide informed consent.

   -

Exclusion Criteria:

1. Patients under 18 years of age.
2. Patients who are pregnant, nursing, or who in the physician's opinion are likely to become pregnant.
3. Patients who are clinically unstable.
4. Patients who have previously been treated with either an endothelin receptor antagonist and stopped due to adverse side effects.
5. Patients with an AST or ALT of >3 x normal.
6. Patients having any known contraindication to the initiation of ambrisentan.
7. Patients with a calculated creatinine clearance of <60ml/min
8. Patients with a serum hemoglobin concentration of <10mg/dl
9. Patients with a poorly controlled cardiac arrhythmia

10. Patients who are unable to provide independent informed consent.

    -

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Ambrisentan first, Placebo second; These patients will be randomized to have ambrisentan during the first study period, and placebo during the second study period.	Drug: Ambrisentan; Other Names: Letaris
Other: Placebo first, Ambrisentan second; These patients will be randomized to have placebo during the first study period, and ambrisentan during the second study period.	Drug: Ambrisentan; Other Names: Letaris

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Change in VO2 Max	Baseline compared to 12 weeks therapy with either ambrisentan or placebo

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Quality of Life	Change in Rand 36-item Short Form (SF-36) physical function score (0-100). On the Rand SF-36 questionnaire, a score closer to 100 (higher) suggests lesser disability, while a score closer to 0 (lower) suggests more disability.	12 weeks

Collaborators and Investigators

• Sponsor: Washington University School of Medicine

Study record dates

Study Major Dates

• Study Start: August 1, 2012
• Primary Completion (Actual): May 1, 2015
• Study Completion (Actual): May 1, 2015

Study Registration Dates

• First Submitted: October 23, 2013
• First Submitted That Met QC Criteria: October 23, 2013
• First Posted (Estimate): October 29, 2013

Study Record Updates

• Last Update Posted (Actual): May 7, 2018
• Last Update Submitted That Met QC Criteria: May 4, 2018
• Last Verified: May 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Congenital Abnormalities; Heart Defects, Congenital; Cardiovascular Abnormalities; Univentricular Heart; Antihypertensive Agents; Ambrisentan
• Other Study ID Numbers: IN-US-300-D076